close
Malva Literature
This is a private area that includes pdf files regarding applications and brochures of our products. Please log in if you are already a member or create a new account.
arium® pro Ultrapure Water Systems
| Drug Discovery & Development |
 |
 |
 |
| Thursday, 12 February 2009 21:19 |
|
A wide range of advanced technologies—including genomics, proteomics, and computational methods—provides tens of thousands of targets that disease-fighting compounds can attack. For a drug to be deemed effective the mode of action must be validated. Moreover, early research must also confirm that a potential drug does not lead to undesirable effects, such as toxicity.
Accurate and efficient methods of target identification and validation remain one of the bottlenecks of drug discovery and development. Advances in the technology behind these pharmaceutical steps—such as employing automation, enhancing data reliability, and improving data analysis—already accelerate the discovery of new drugs.
The high number of potential targets to identify and validate demand instruments that drive throughput and improve data quality and analysis. For example, our Twister II is capable of handling 400 microplates—all in a simple plug-and-play solution. Likewise, the LabChip GX suite of instruments provides automated electrophoresis to analyze quality, size, and concentration, of DNA, RNA, and proteins.
With the acquisition of NovaScreen Biosciences and Xenogen Biosciences, Caliper established itself as a leader in contract research. The combination of these two companies spawned Caliper Discovery Alliances & Services (CDAS). CDAS ideally placed to improve its customer’s “batting average” as development moves from in vitro to in vivo studies and testing. CDAS’s combined services include more than 800 in vitro assays—covering G-protein coupled receptors (GCPR binding), kinases, toxicity panels, and more. CDAS also provides more than 85 in vivo services, such as assays that target disease-related genes, creating transgenic animals, developing animal models of disease, and measuring a compound’s phenotypic result.
These Caliper tools and services overcome some of the most fundamental hurdles in target identification and validation—automation, throughput, data quality and analysis.
Overall, Caliper simplifies, speeds up, and improves a wide range of target identification and validation steps utilizing technologies like Genomics and Proteomics. As a result, drug discovery and development moves ahead more efficiently and economically—all while improving the safety and efficacy.
http://www.caliperls.com/apps/drug-discovery-and-pre-clinical-development/target-id-validation.htm |
| Last Updated on Tuesday, 03 January 2012 13:36 |